Article
Author(s):
Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program.
Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program. Under the agreement, Laureate will produce ARIUS’s IgG1 humanized antibody. ARIUS’s Trop-2 antibody program targets a novel marker that has been linked to aggressive cancers including pancreatic, colon, breast, and prostate cancer.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.